A Phase 1b Study to Evaluate the Safety and Tolerability of Andecaliximab (GS-5745) as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Subjects With Gastric or Gastroesophageal Junction Adenocarcinoma

Trial Profile

A Phase 1b Study to Evaluate the Safety and Tolerability of Andecaliximab (GS-5745) as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Subjects With Gastric or Gastroesophageal Junction Adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Sep 2017

At a glance

  • Drugs Andecaliximab (Primary)
  • Indications Gastric cancer
  • Focus Adverse reactions
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 29 Aug 2017 Planned number of patients changed from 18 to 38.
    • 13 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 16 May 2017 Planned End Date changed from 1 Jul 2018 to 1 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top